SKY-LABS
22.2.2021 15:02:11 CET | Business Wire | Press release
Sky Labs , a healthcare start-up, announced that CART-I, its ring-type heart-monitoring device, had been provided for Timothy Betts, professor of medicine at Oxford University, for his clinical research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005010/en/
Professor Timothy Betts is a cardiologist and arrhythmia specialist. He is a key figure for clinical research in cardiac rhythm management and associate professor of cardiovascular medicine at Oxford University. He is also a member of the Oxford Biomedical Research Center and the UK representative on the EHRA National Cardiac Societies Committee.
Atrial fibrillation patients are advised to take anticoagulants to prevent the risk of stroke. However, it is not easy to identify the symptoms. Professor Betts plans to conduct a clinical study with Sky Labs CART-I, Medtronic Reveal LINQ II and Apple Watch to detect atrial fibrillation symptoms and alert the patients to take anticoagulants when needed.
Fifty patients recruited for the study will be inserted with a Reveal LINQ II implantable cardiac monitor (ICM). Then they will receive a Sky Labs CART-I ring or an Apple Watch. The ability of the ring and the watch to monitor heart rhythm and alert atrial fibrillation episodes will be analyzed in comparison with the ICM.
CART-I is the world’s first ring-type heart-monitoring device. The photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger and continuously measures the irregular pulse waves of atrial fibrillation. Electrocardiogram (ECG) can be also measured by simply placing the fingers on the metal part of the ring.
Professor Timothy Betts said, “I’m pleased to conduct a study to monitor the atrial fibrillation of patients by using CART-I and utilize the data to guide atrial fibrillation treatment. CART-I featuring innovative design and multiple functions will be of great help to patients and medical staffs.”
Jack Lee, CEO of Sky Labs, said, “The study will be an opportunity for us to enter the global healthcare market. CART-I will make a good combination with the ICM in monitoring heart rhythm and providing meaningful data for patients and doctors.”
Sky Labs’ CART-I won the Digital Health & Technology Competition of the European Society of Cardiology for 2 consecutive years from 2018. The company was selected as the ‘technology pioneer’ of the World Economic Forum 2019 and invited to the annual forum.
About Sky Labs
Sky Labs developed CART (Cardio Tracker) – I, a ring-type medical device to monitor heart signals and detect diseases by using optical sensors. It monitors atrial fibrillation, which cannot be detected in advance, 24/7. The results can be checked in real time on the CART-app of your smartphone. Very light and water-resistant, the CART ring is easy to use and causes no inconvenience to your daily life. Winning the final of the Grants4Apps held by Bayer, a German multinational pharmaceutical company, in 2017, Sky Labs attracted investment from Bayer Headquarters. Sky Labs and the Charité in Germany, one of Europe’s largest hospitals, have been considering collaborative clinical research in heart-related diseases since May 2018. It is the only Korean company which won the Digital Health and Technology Competition of the European Society of Cardiology for 2 consecutive years. In addition, the company was invited as a technology pioneer to the World Economic Forum 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom